Keyword: Harvard Pilgrim Health Care
AstraZeneca is looking to boost its key inhaler with two outcomes-based deals with regional insurers.
The numbers behind NICE's choice to endorse Strimvelis show just how tough it can be to make money from gene therapy.
Pay-for-performance deals have been gaining popularity among drugmakers, and Harvard Pilgrim has been ready and willing to strike up partnerships. The latest to do so? AstraZeneca.